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Background: Identiﬁcation of wound-speciﬁc markers would represent an important step toward da-
maged tissue detection and targeted delivery of biologically important materials to injured sites. Such
delivery could minimize the amount of therapeutic materials that must be administered and limit po-
tential collateral damage on nearby normal tissues. Yet, biological markers that are speciﬁc for injured
tissue sites remain elusive.
Methods: In this study, we have developed an immunohistological approach for identiﬁcation of protein
epitopes speciﬁcally exposed in wounded tissue sites.
Results: Using ex-vivo tissue samples in combination with ﬂuorescently-labeled antibodies we show that
actin, an intracellular cytoskeletal protein, is speciﬁcally exposed upon injury. The targetability of actin in
injured sites has been demonstrated in vivo through the speciﬁc delivery of anti-actin conjugated par-
ticles to the wounded tissue in a lethal rat model of grade IV liver injury.
Conclusions: These results illustrate that identiﬁcation of injury-speciﬁc protein markers and their tar-
getability for speciﬁc delivery is feasible.
General signiﬁcance: Identiﬁcation of wound-speciﬁc targets has important medical applications as it
could enable speciﬁc delivery of various products, such as expression vectors, therapeutic drugs, he-
mostatic materials, tissue healing, or scar prevention agents, to internal sites of penetrating or surgical
wounds regardless of origin, geometry or location.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There are a milieu of biochemical and physiological events at a
wound site due to structural changes resulting from cell lysis or
tissue rupture and the associated displacement of intracellular or
extracellular proteins from their natural locations. Studies in
model organisms, such as zebraﬁsh, demonstrated that myocel-
lular injury leads to expression of speciﬁc markers, such as Xin-
actin-binding repeat-containing proteins (Xirp), with a potential
role in cytoskeletal reorganization and muscle regeneration [13].
Other studies have shown that injury of the blood vessel wall and
surrounding extracellular matrix by mechanical rupture or heat
results in irreversible unfolding of collagen from its native state
[22], generating signals for induction of arteriolar vasodilation andB.V. This is an open access article u
nt Drive, SanDiego, CA 92121.
s).
.increase in blood ﬂow to the injured area [10]. In addition, necrotic
cells resulting from tissue injury can be detected by the immune
system through recognition of damage-associated molecular pat-
terns (DAMPs) by dendritic cell receptors, leading to inﬂammatory
response and tissue repair [2,16]. Identiﬁcation of targetable
wound-speciﬁc markers would represent a viable mechanism for
the detection and speciﬁc delivery of biologically important ma-
terials to wound surfaces, such as therapeutic or hemostatic pay-
loads. Additionally, identiﬁcation of such targets might be ad-
vantageous in minimizing administered dosages, improve the
availability due to increased local delivery, and avoid potential
deleterious interactions with nearby healthy tissue. Wound tar-
geting would also enable binding to non-compressible, asymme-
trically exposed internal organ areas as a result of penetrating or
surgical wounds, irrespective of geometry and location. To date,
however, biological epitopes that are speciﬁc to injured tissue sites
remain largely unknown.
The objective of this study was to identify protein markers that
become rapidly exposed in wounded animal tissues and might bender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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apeutic products to the trauma surface, irrespective of wound
shape and/or location. We hypothesized that rapid site detection
and wound-speciﬁc delivery of medical products would require
recognition of structural, physical and/or biochemical signatures
unique to the damaged tissue that are present at the wound site
immediately upon injury. To this end, we developed a method for
screening and identifying proteins that are rapidly and speciﬁcally
exposed in injured animal tissues. Using this approach, we iden-
tiﬁed an abundant cytoskeletal protein as a wound marker and
evaluated its targetability for localized delivery of materials at the
site of the wound both ex vivo and in vivo.2. Materials and methods
2.1. Reagents
2-(N-morpholino)ethanesulfonic acid (MES) buffer, Bovine
serum albumin (BSA) and NaN3 were purchased from Sigma-Al-
drich Corporation, MI. Fetal Bovine Serum (FBS) Hyclone, 10%
Neutral Buffered Formalin, Tissue Tek optimum cutting tempera-
ture (O. C. T.) compound, sucrose, and Fluorescent Mounting
Media were purchased from VWR International, PA. Tween-20 10%
was purchased from Bio-Rad Laboratories, CA. Carboxylated
ﬂuorescent (505/515) 2 mm beads were purchased from Invitrogen,
CA. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-
chloride (EDC) and N-hydroxysulfosuccinimide (Sulfo-NHS) were
purchased from Thermo Scientiﬁc, IL. DAPI (4′,6-Diamidino-2-
Phenylindole, Dihydrochloride) was purchased from Thermo
Fisher Scientiﬁc, MA.
2.2. Antibodies
Anti-β-Actin-Fluorescein isothiocyanate (FITC) mouse mono-
clonal antibody and mouse IgG1 anti-β-actin were purchased from
Sigma-Aldrich Corporation, MI. Alexa-488 donkey anti-mouse IgG
and goat anti-mouse IgG1 were purchased from Jackson Im-
munoResearch, PA. Anti-collagen I, anti-Elastin, anti-Entactin and
mouse IgG1 anti-human IgM were purchased from AbCam, MA.
Alexa 488 anti-S6 ribosomal 54D2 antibody was purchased from
Cell Signaling Technology, MA.
2.3. Antibody ﬂuorescent labeling
Anti-Collagen I, anti-Elastin, anti-Entactin and mouse IgG1
anti-human IgM were FITC-labeled using N-Hydroxysuccinimide
(NHS)-Fluorescein (Thermo Fisher Scientiﬁc, MA) according to
manufacturer's recommendations with slight modiﬁcations.
Brieﬂy, the antibody sample (1 mg/mL) was mixed with freshly
reconstituted NHS-Fluorescein in DMSO and the labeling reaction
was incubated overnight (12–16 h) at 4 °C. The labeled antibody
was then separated from excess ﬂuorescein reagent utilizing Mi-
croSpin G-25 columns (GE Healthcare Bio-Sciences Corporation,
PA) per the manufacturer's recommended conditions. Protein
concentration in the eluant was estimated utilizing the Pierce™
BCA Protein assay kit (Thermo Fisher Scientiﬁc, MA). The efﬁciency
of antibody ﬂuorescence labeling was measured using a Mithras LB
940 multimode microplate reader (Berthold Technologies, TN).
Antibody preparations used in these studies had similar speciﬁc
ﬂuorescence intensities.
2.4. Ex vivo tissue samples
Rat tissues for ex vivo experiments were harvested from heal-
thy male Sprague-Dawley rats and immediately snap frozen inliquid nitrogen. Rat liver tissue was purchased from BioChemed
Services (Winchester, VA) or Analytical Biological Services, Inc.
(Wilmington, DE). Rat kidney and rat spleen tissues were pur-
chased from Innovative Research, Inc. (Novi, MI). Rat skeletal
muscle tissue was purchased from BioreclamationIVT (Liverpool,
NY). Bovine whole blood with sodium heparin anticoagulant was
purchased from Innovative Research, Inc. (Novi, MI).
2.5. Tissue injury ex vivo and wound targets screening
The rat tissue samples (approximately 222 cm3 in size)
were thawed at 4 °C and, depending on the type of tissue, dis-
section scissors, forceps, or razor blades were used to create an
X-shaped wound. The wounds covered the majority of the surface
area, measuring approximately 1.5 cm in diameter and cutting all
the way through the tissue, top to bottom. Immediately following
injury, the tissue samples were placed in 5 mL cold blocking so-
lution (10% FBS in PBS) and incubated for 1 h at 4 °C. FITC-labeled
antibodies against the potential injury-speciﬁc target epitopes (or
anti-mouse IgG as negative control) were diluted in blocking so-
lution (500 mL at a ﬁnal concentration of 0.05 mg/mL) and added to
tissue samples followed by incubation at 4 °C for 1 h. After anti-
body incubation, 1 mL cold PBST (0.1% Tween-20 in PBS) was ad-
ded to the wound to remove unbound antibody (total of two
washes). The samples were ﬁxed by placement in a 35 mL cold 10%
Neutral Buffered Formalin (VWR International, PA) followed by
overnight ﬁxation at 4 °C. Samples were then placed in 35 mL cold
30% Sucrose/PBS overnight at 4 °C for cryoprotection. The samples
were mounted into cryomolds in O.C.T. medium, with the
X-shaped wound facing the bottom of the cryomold, and placed in
a 70 °C freezer. Frozen blocks were shipped to Molecular Diag-
nostic Services (CA) for cryosectioning using a microtome to 10-
micron thick sections, and mounting of the tissue sections onto
microscope slides. For analysis, slides were warmed to room
temperature and submerged in PBS for 5 min before applying
Fluorescent Mounting Media (VWR International, PA) and cover-
slips. Tissue slides were viewed using an Olympus IX51 inverted
microscope (Olympus, MA). Images were captured using a Mi-
croFire™ digital microscope imaging camera and Picture Frame™
software (Optronics Engineering Ltd., TX). For nuclear staining,
tissue sections were incubated with DAPI [(100 ng/mL in phos-
phate-buffered saline (PBS))] in dark for 5 min at room tempera-
ture prior to ﬂuorescence imaging. For testing antibody binding in
the presence of blood, wounded tissue samples were immersed in
bovine blood and incubated for 1 h with FITC-labeled antibodies
(anti-β-actin or IgG) previously diluted in heparinized bovine
blood (antibody ﬁnal concentration 0.05 mg/mL). The rest of the
experimental processes were performed essentially as described
above.
For quantitative analysis of the speciﬁc signal increase within
the injury sites relative to uninjured tissue, images from tissues
treated with ﬂuorescently labeled antibodies were converted to
grayscale and multiple representative rectangular regions were
selected from the wounded surface as well as the neighboring
healthy tissue (Supplemental Fig. 1). Quantitative analysis was
performed as an aggregate for all selected wounded regions. Same
analysis was performed for the selected healthy tissue regions to
represent the background. The resulting mean values and standard
deviations were calculated and graphically represented using
Matlab R2013b software (MathWorks, Natick, MA).
2.6. Microbead-antibody conjugation
Yellow-green ﬂuorescent carboxylate-modiﬁed microspheres
(nominal bead diameter of two microns) (Thermo Fisher Scientiﬁc,
MA) were washed by mixing 500 mL of beads suspension (2%) with
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5000 g for three minutes. The supernatant was discarded and
the beads were re-suspended in 800 mL of the same buffer. Freshly
prepared EDC (40 mL, 100 mg/mL) was then added to the beads
followed by mixing and addition of freshly prepared sulfo-NHS
(160 mL, 50 mg/mL). The mixture was placed in a shaking incubator
at 1400 rpm for 15 min at room temperature. Beads were spun
down and the supernatant discarded. The beads were re-sus-
pended in 1 mL PBS, pelleted, and re-suspended in one mL solu-
tion consisting of equal volumes of PBS and goat anti-mouse IgG1
(1.2 mg/mL) followed by overnight incubation on an orbital shaker
at 4 °C. The beads were pelleted by centrifugation at 5000 g for
three minutes and re-suspended in one mL of 40 mM glycine so-
lution followed by incubation on an orbital shaker for 30 min at
room temperature. The beads were sonicated in a water bath for
30 min and vortexed to disperse any clumps. The beads were then
washed in buffer A (PBS, 1% BSA, 0.5% Tween-20) and re-sus-
pended in one mL of sample buffer (PBS, 1% BSA, 0.05% Tween-20,
0.02% NaN3/PBS). Anti-actin or anti-IgG antibody (200 mL,
2 mg/mL) were then added and the solution was mixed on an
orbital rocker for 2 h at room temperature, followed by 72 h at
4 °C. At the end of the incubation period, beads were pelleted,
washed twice in 500 mL of sample buffer, re-suspended in the
same buffer, and stored at 4 °C.
2.7. Wound site recognition by antibody-conjugated microbeads
All animal research activities were conducted at the Lovelace
Respiratory Research Institute (LRRI) under an Institutional Animal
Care and Use Committee (IACUC) approved animal use protocol.
Male Sprague-Dawley rats (approximately 300 g) were anesthe-
tized via isoﬂurane inhalation and subjected to mid-line ventral
incision. The large liver lobe was isolated and severe parenchymal
hemorrhage was created by laceration of a section of the ventral
surface with a curved set of surgical scissors, generating a grade IV
open abdomen trauma. Wounds were approximately
1.5 cm0.75 cm0.4 cm (2.1–5.6% of the total liver weight, as
determined post-experimentation; approximate excised tissue
volume was 600–700 mL). At ﬁve minutes post injury (blood loss
was approximately 0.5 mL/min), ﬂuorescently labeled polystyrene
beads (500 mL, 2106 beads/mL in sample buffer), tagged with
either anti-actin antibodies (for wound targeting) or anti-IgG
(negative control), were applied to the wound over a 30 s period.
Ninety seconds after the beads were applied, the animal was eu-
thanized and the liver removed. The injured lobe was separated
from the rest of the liver and the wound was washed four times
with 1 mL of cold buffer consisting of PBS, 0.1% Tween-20% and
0.02% NaN3/PBS. Liver tissue was then ﬁxed and processed for
ﬂuorescence imaging as described previously.
Conjugated microparticle testing ex vivo was performed es-
sentially as described above using excised rat liver subjected to
X-shaped wound. In these experiments, 200 mL of blocking solu-
tion was applied to the wound and incubated for two minutes
followed by addition of polystyrene beads (83 mL, 5106 beads/mL
in sample buffer) and incubation for 2 min. The wound was wa-
shed four times with PBS, 0.1% Tween-20 solution, and the tissue
was ﬁxed, cryo-sectioned, and imaged as described previously.3. Results
3.1. Screening against protein epitopes exposed in wounded tissue
The speciﬁc injury-induced exposure of candidate protein epi-
topes was tested in a rat injured liver tissue ex-vivo. A schematic
description of the experimental process is illustrated in Fig. 1A. Inthese experiments, animals were euthanized and the tissue was
excised from the body and immediately snap frozen. Upon thaw-
ing, the tissue was lacerated and incubated with labeled (ﬂuor-
esceinated) antibodies against the candidate target epitopes or
with non-speciﬁc IgG antibodies as negative control. Following
tissue ﬁxation and cryosectioning, the slides containing tissue
samples were examined using ﬂuorescence imaging microscopy
for the identiﬁcation of protein targets that are exposed in injured
tissue as a means of their interaction with their cognate labeled
antibodies. For a candidate epitope to be identiﬁed as a wound
target, the signal from the labeled antibody should be localized in
the wounded tissue surface rather than the surrounded healthy
tissue area and be higher than the signal generated by the in-
cubation of a wounded surface with a negative control antibody.
The list of candidate wound epitope targets included proteins
that were expected to be exposed at high concentrations in the
wounded area upon cell lysis caused by trauma and also of par-
tially insoluble nature so that they would be able to remain at the
injured site despite the potential presence of signiﬁcant blood
ﬂow. Criteria for inclusion of a candidate target epitope to the
screening list also included the availability of an antibody against
that epitope as well as lack of signiﬁcant cross reactivity of avail-
able antibodies toward other epitopes. As a result, the list of
candidate wound epitope targets consisted of intracellular pro-
teins, such as cytoskeletal (actin and myosin), nuclear (histones)
and cytosolic (ribosomal) proteins, as well as extracellular matrix
proteins, such as collagen I (among the most abundant arterial
wall proteins), entactin (a component of the basement mem-
brane), and elastin (a component of the vessel wall).
3.2. Identiﬁcation of actin as a wound-speciﬁc target epitope
Antibodies against the aforementioned candidate protein tar-
gets were obtained and labeled with ﬂuorescein. The results in-
dicated that anti-β-actin antibody binds to the edges of the wound
but not to surrounding healthy tissue of rat liver and that such
wound site binding generates a signal that is signiﬁcantly stronger
than the signal observed using labeled control IgG (Fig. 1B and C).
In contrast to actin, negligible binding to the injured site was ob-
served using antibodies against other intracellular proteins, such
as ribosomal proteins, histone, and myosin, or extracellular matrix
proteins, such as collagen I, entactin and elastin (Fig. 1D). Results
from the quantitative analysis of the data are shown in Fig. 1E il-
lustrating the stronger binding to wounded areas versus nearby
healthy tissues of actin antibody relative to other antibodies
tested.
After demonstrating that β-actin was exposed in injured rat
liver tissue, we tested whether this protein represents an injury
recognition target for other tissues as well. The results in Fig. 2
demonstrated that actin is exposed in injured rat spleen, kidney
and skeletal muscle tissues, suggesting its broad applicability as an
injury-speciﬁc epitope. Preliminary assessment of the binding ki-
netics of actin recognition at the wound area, performed by in-
cubating the antibody with the tissue for different time frames,
indicated that wound-speciﬁc binding occurs within 30 s (Fig. 3A
and B). In addition, the targetability of this protein was not hin-
dered by the presence of blood in the wounded area as shown in
experiments where the ex vivo wound tissue was immersed in
blood prior to the application of the FITC anti-actin antibody
(Fig. 3C and D).
3.3. Wounded tissue recognition by microparticles coated with anti-
actin antibodies
These results suggest that actin represents a potential wound-
speciﬁc target that can be used for materials delivery to injured
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Fig. 1. Identiﬁcation of actin as a wound-speciﬁc marker. (A). Outline of the experimental procedure for identiﬁcation of protein targets exposed in injured tissue sites. Tissue
samples are removed from the animal upon euthanization and lacerated under controlled conditions. Tissue samples are incubated with labeled (ﬂuorescein) antibodies
against the candidate target epitopes or with labeled non-speciﬁc antibodies (IgG) as negative controls. Tissue samples are then ﬁxed, subjected to fast freezing and
cryosectioning, and examined using ﬂuorescence imaging microscopy. Microscopy images are captured and analyzed to assess whether the target epitopes were exposed in
injured tissue areas as a means of their speciﬁc interaction with their cognate labeled antibodies. (B). Traumatized rat liver tissue treated with ﬂuoresceinated (FITC-labeled)
antibody against actin (top panel) or IgG (bottom panel). Images are representative of a series of horizontal slices across a vertical injury. Pictures were taken using inverted
microscopy at 10 magniﬁcation. (C). Fluorescence image of tissue sample treated with FITC-labeled anti-actin (green) and ﬂuorescent nuclear counterstain, DAPI (blue).
(D). Screening against intracellular (top panels) or extracellular matrix (bottom panels) proteins for speciﬁc wound exposure. (E). Quantitative analysis (mean and standard
deviation) of image intensities at the wounded surface versus the neighboring healthy tissue areas for the wound targets tested.
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tion, we assessed transport and wound-speciﬁc binding of poly-
styrene beads as surrogate carrier particles conjugated to anti-
bodies recognizing actin epitopes exposed in wounded tissues
ex vivo. The results of these experiments showed that beads con-
jugated to anti-actin antibodies speciﬁcally bind to injured liver
tissue (Fig. 4A).
Next, we evaluated transport and wound-speciﬁc binding of
the aforementioned microparticles in vivo using an aggressive
anesthetized bleeding animal model. In these experiments, poly-
styrene beads were tagged with either anti-actin antibodies (for
wound targeting) or anti-IgG (negative control). Anesthetized rats
were subjected to a grade IV lethal liver injury and allowed to
bleed for a total of ﬁve minutes before the antibody-coated bead
sample was applied to the wound in the presence of blood ﬂow
(see Materials and Methods section for experimental details).
Following treatment, the animals were euthanized, and the liver
harvested, washed, ﬁxed and sectioned for ﬂuorescence micro-
scopy. The results (Fig. 4B) show speciﬁc targeting of the wound
site in vivo, providing feasibility for use of actin as a target for
speciﬁc delivery of materials to an aggressively bleeding wound
site.4. Discussion
In this study we describe an approach for identiﬁcation of in-
jury-speciﬁc protein markers that are rapidly exposed in wounded
tissues and can be targeted for localized delivery of compounds of
interest speciﬁcally at the affected area immediately upon trauma.
Using this approach we discovered actin as such injury-speciﬁc
marker. Wound-speciﬁc exposure of actin was veriﬁed in various
animal tissues, suggesting the targetability of this protein in-
dependently of tissue type. We further showed that this marker is
exposed in trauma areas within seconds upon tissue damage and
remains stable over time and in the presence of blood. Im-
portantly, by exploiting this protein as a wound-speciﬁc target, we
selectively delivered microparticles conjugated to actin antibodies
to injured areas in an ex vivo model of animal tissue trauma and an
in vivo model of lethal animal injury. Given that tissue injury re-
sults in cell lysis and exposure of intracellular components nor-
mally not present on the cell surface, it is anticipated that the
method described here for discovery of wound-speciﬁc epitopes,
and the identiﬁcation of actin as such marker, will be broadly
applicable regardless of wound size and/or location.
Actin represents one of the most evolutionarily conserved and
abundant intracellular eukaryotic proteins, providing a potentially
high concentration of target epitopes for wound recognition. In
addition, in its cytoskeletal form, actin is only partly soluble, a
Wounded surface
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Fig. 2. Actin recognition in injured sites of various tissues. (A). Traumatized rat spleen (left), kidney (middle) or muscle (right) tissues were treated with ﬂuoresceinated
(FITC-labeled) antibody against actin (top panels) or IgG as negative control (bottom panels). (B). Quantitative analysis (mean and standard deviation) of image intensities at
the wounded surface versus the neighboring healthy areas for spleen, kidney and muscle tissues treated with anti-actin (top panel) or IgG (bottom panel) antibodies.
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Fig. 3. Availability of actin epitope in wounded tissue. (A). Fluorescence images from experiments assessing wound-speciﬁc binding of FITC-labeled anti-actin antibodies
upon incubation with injured rat liver ex vivo for various time periods. (B). Quantitative analysis (mean and standard deviation) of image intensities at the wounded surface
versus the neighboring healthy tissue areas upon incubation of injured tissue samples with anti-actin antibody for various incubation times. (C). Targeting of actin in
wounded rat liver tissue immersed in blood (left panels) or in the absence of blood (right panels). Excised wounded liver tissue in each case was treated with either FITC-
labeled antibody against actin (top panels) or FITC-labeled IgG antibody as negative control (bottom panels). (D). Quantitative analysis of image intensities at the wounded
surface versus the neighboring healthy tissue areas for tissue samples treated with anti-actin (top panel) or IgG (bottom panel) antibodies in the presence or absence of
blood.
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Fig. 4. Anti-actin-conjugated beads binding to wounded liver tissue ex vivo and in vivo. (A). Anti-actin-conjugated beads binding to injured liver tissue ex vivo. Excised liver
tissue was incubated with labeled polystyrene beads conjugated to either anti-actin antibodies (left panel) or IgG as negative control (right panel). (B). Assessment of actin as
a wound-speciﬁc biomarker in vivo. Transport and wound-speciﬁc binding was tested in a grade IV anesthetized rat lethal liver injury model. Lacerated liver tissue was
incubated with labeled polystyrene beads conjugated to either anti-actin antibody or IgG (negative control). Following treatment, the anesthetized animals were euthanized,
and the livers harvested, washed, ﬁxed and sectioned for ﬂuorescence microscopy. Left panel: Typical liver injury generated in this procedure. Middle panel: Beads tagged
with anti-actin antibodies. Right panel: Beads tagged with IgG.
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signiﬁcant blood ﬂow. This attribute of actin was evident in our
study through its targetability under conditions of aggressive
bleeding in vivo. In accordance with these results, it was recently
found that cell death does not lead to complete loss of cytoske-
leton structural integrity; instead damaged cells retain poly-
merized actin ﬁlaments that upon exposure serve as a signal to
initiate a controlled immune response toward tissue repair [2].
Another signiﬁcant attribute of actin as a wound target is that its
presence at the injured site does not require de novo synthesis;
this protein is present intracellularly (thus not available for bind-
ing in healthy tissue) but becomes exposed upon cell lysis caused
by injury. Accordingly, the availability of this wound-speciﬁc target
is expected to be rapid upon trauma. In agreement with this hy-
pothesis, our experiments suggested that binding of actin anti-
bodies to injury-exposed actin occurs within 30 s.
Identiﬁcation and subsequent utilization of wound-speciﬁc
targets could have important applications. For example, it would
allow target recognition moieties to be multivalently bound to the
surface of small size particles (liposomes, nanoparticles, or other
type carriers), thus allowing targeted delivery of therapeutic loads
to virtually any wound area regardless of geometry and in-
tracavitary location. Targeted delivery to injured sites can mini-
mize the amount of therapeutic agents and materials that must be
delivered to a wound area, improve the speciﬁcity of delivery to
the critical site of tissue damage, and minimize potential collateral
damage to the surrounding healthy tissue. In this regard, it is
envisioned that wound-speciﬁc targets can be utilized in the clinic
to enable targeted delivery of agents that attenuate blood losscaused by penetrating wounds or surgical trauma to the skin or
internal organs. Wound-targeting systems can be administered
directly to the injured site, such as by irrigation of the wound with
a solution containing a particular composition, or systemically,
such as by intravenous delivery, upon optimization for increased
circulatory life-time and reduced clearance by the immune system.
Wound targeting moieties can include polyclonal, monoclonal,
chimeric and humanized antibodies (or antigen-binding fragment
regions) or peptides with afﬁnity for one or more epitopes within
the speciﬁc protein target of interest. Those targeting moieties can
be conjugated on the surface of nano- or microparticles using a
variety of techniques, including covalent conjugation to poly-
ethylene glycol (PEG) strands at the surface of the particles [11] or
use of biotinylated [15], amine-reactive [3,18,23,24] and thiol-re-
active copolymers [12,19] that permit protein chemical conjuga-
tion under non-denaturing conditions [6,14]. Types of carriers may
include, for example, liposomes or various types of nanoparticles
[1,4,7,17,21], microspheres [8], nanospheres [5], micelles [9,20],
and dendrimers [25]. In support, our preliminary results have
demonstrated successful wound-speciﬁc recognition of injured rat
liver tissue by liposome particles conjugated to anti-actin anti-
bodies and carrying encapsulated peptide payloads (to be de-
scribed elsewhere).
In conclusion, we have identiﬁed actin as an injury-speciﬁc
protein marker that gets exposed at the wounded site upon cell
damage. The identiﬁcation of actin as a wound-speciﬁc target
suggests that abundant proteins with housekeeping functions can
be explored as potential targets for speciﬁc delivery of therapeutic
materials to injured sites. Identiﬁcation of damaged tissue-speciﬁc
E.D. Pendleton et al. / Biochemistry and Biophysics Reports 7 (2016) 56–6262biomarkers has the potential for fundamentally impacting human
care and trauma patient outcomes.Conﬂict-of-interest statement
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